Indian Court Rejects Whistle Blower’s Suit Seeking Regulatory Fixes
This article was originally published in PharmAsia News
Executive Summary
India's apex court has declined to admit Ranbaxy whistleblower Dinesh Thakur's petitions that sought "urgent intervention" to improve India's drug regulatory standards and challenged the constitutionality of certain rules under the Drugs and Cosmetics Rules 1945.